JAK2 and non-small cell lung carcinoma: IL-6 activated the JAK2/p-STAT3 pathway in NSCLC cells, which exerts a synergistic effect with ALKBH5, thus maintaining an immunosuppressive microenvironment that drives tumorigenesis.